Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials

Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated incons...

Full description

Bibliographic Details
Main Authors: Patrick M. McCarthy, Franklin A. Valdera, Todd R. Smolinsky, Alexandra M. Adams, Anne E. O’Shea, Katryna K. Thomas, Spencer Van Decar, Elizabeth L. Carpenter, Ankur Tiwari, John W. Myers, Diane F. Hale, Timothy J. Vreeland, George E. Peoples, Alex Stojadinovic, Guy T. Clifton
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
tumor infiltrating lymphocyte (TIL)
cancer vaccine
vaccination
endpoint
immunotherapy
checkpoint inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/full

Similar Items